ATE105858T1 - Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung. - Google Patents

Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung.

Info

Publication number
ATE105858T1
ATE105858T1 AT87110417T AT87110417T ATE105858T1 AT E105858 T1 ATE105858 T1 AT E105858T1 AT 87110417 T AT87110417 T AT 87110417T AT 87110417 T AT87110417 T AT 87110417T AT E105858 T1 ATE105858 T1 AT E105858T1
Authority
AT
Austria
Prior art keywords
fmdh
dna
protein
activity
molecules
Prior art date
Application number
AT87110417T
Other languages
English (en)
Inventor
Cornelius P Hollenberg
Zbigniew Janowicz
Original Assignee
Rhein Biotech Ges Fuer Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Biotech Ges Fuer Biotech filed Critical Rhein Biotech Ges Fuer Biotech
Application granted granted Critical
Publication of ATE105858T1 publication Critical patent/ATE105858T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2414—Alpha-amylase (3.2.1.1.)
    • C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
    • C12N9/242—Fungal source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01002—Formate dehydrogenase (1.2.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/02—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a cytochrome as acceptor (1.2.2)
    • C12Y102/02001—Formate dehydrogenase (cytochrome) (1.2.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
AT87110417T 1987-07-17 1987-07-17 Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung. ATE105858T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP87110417A EP0299108B1 (de) 1987-07-17 1987-07-17 DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung
AU24434/88A AU2443488A (en) 1987-07-17 1988-10-27 Dna-molecules coding for fmdh control regions and structured gene for a protein having fmdh-activity and their uses
JP63277205A JP3072993B2 (ja) 1987-07-17 1988-11-01 Ｄｎａ分子
US07/844,885 US5389525A (en) 1987-07-17 1992-03-03 DNA-molecules coding for FMDH control regions and structural gene for a protein having FMDH-activity and their use thereof

Publications (1)

Publication Number Publication Date
ATE105858T1 true ATE105858T1 (de) 1994-06-15

Family

ID=27422777

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87110417T ATE105858T1 (de) 1987-07-17 1987-07-17 Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung.

Country Status (7)

Country Link
US (1) US5389525A (de)
EP (1) EP0299108B1 (de)
JP (1) JP3072993B2 (de)
AT (1) ATE105858T1 (de)
AU (1) AU2443488A (de)
DE (1) DE3789866T2 (de)
ES (1) ES2056799T3 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL168787B1 (pl) * 1989-08-03 1996-04-30 Smithkline Beecham Biolog Sposób wytwarzania czastki kompozytowej PL
EP2289548A3 (de) 1992-05-23 2012-08-08 GlaxoSmithKline Biologicals S.A. Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
SG49909A1 (en) 1992-06-25 1998-06-15 Smithkline Beecham Biolog Vaccine composition containing adjuvants
AU6415594A (en) * 1993-03-25 1994-10-11 Biosource Genetics Corporation (pichia pastoris) alcohol oxidase (zza1) and (zza2)
US6358722B1 (en) 1994-04-25 2002-03-19 Roche Vitamins, Inc. Heat tolerant phytases
US6699704B1 (en) 1994-04-25 2004-03-02 Roche Vitamins Inc. Heat tolerant phytases
US5712114A (en) * 1995-06-06 1998-01-27 Basf Aktiengesellschaft Compositions for expression of proteins in host cells using a preprocollagen signal sequence
JP3396224B2 (ja) * 1995-09-12 2003-04-14 麒麟麦酒株式会社 カンジダ・ボイジニイのギ酸脱水素酵素遺伝子のプロモーター／ターミネーター
EP0862640A2 (de) * 1995-11-09 1998-09-09 ZymoGenetics, Inc. Herstellung von gad65 in methylotrophen hefen
US5955349A (en) * 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5716808A (en) * 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
US5747328A (en) * 1996-02-28 1998-05-05 Wisconsin Alumni Research Foundation Microbial system for formaldehyde sensing and remediation
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
CA2231948C (en) 1997-03-25 2010-05-18 F. Hoffmann-La Roche Ag Modified phytases
NZ330940A (en) 1997-07-24 2000-02-28 F Production of consensus phytases from fungal origin using computer programmes
EP1659173A1 (de) 1997-10-01 2006-05-24 DSMIP Assets B.V. Verfahren zur Protein-Herstellung
GB9724627D0 (en) 1997-11-20 1998-01-21 Genencor Int Bv Gram positive microorganism formate pathway
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
US6720174B1 (en) 1999-01-28 2004-04-13 Novozymes A/S Phytases
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US6645739B2 (en) 2001-07-26 2003-11-11 Phoenix Pharmacologies, Inc. Yeast expression systems, methods of producing polypeptides in yeast, and compositions relating to same
WO2003054155A2 (en) 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
EP1994409A2 (de) 2006-03-14 2008-11-26 Oregon Health and Science University Verfahren zum hervorrufen einer immunantwort auf tuberkulose
CA2662064A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Method of producing a combination polivirus vaccine
DK2106447T3 (da) 2007-01-26 2013-06-24 Novozymes As Fremgangsmåde til methanoluafhængig induktion fra methanolinducerbare promotorer i Pichia
AU2008221383B2 (en) 2007-02-28 2012-09-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
BRPI0810778A2 (pt) 2007-05-02 2011-09-13 Glaxosmithkline Biolog Sa kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
US9005631B2 (en) 2008-08-04 2015-04-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Membrane proximal region of HIV gp41 anchored to the lipid layer of a virus-like particle vaccine
US8664183B2 (en) 2009-02-27 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SPANX-B polypeptides and their use
US9181306B2 (en) 2009-10-16 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
EP2336152B1 (de) 2009-12-21 2014-08-13 Süd-Chemie IP GmbH & Co. KG Thermostabile Xylanase für die selektive Hydrolyse von pentosehaltigen Polysacchariden
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
US9566329B2 (en) 2012-04-06 2017-02-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live, attenuated rubella vector to express vaccine antigens
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
PE20151720A1 (es) 2013-03-08 2015-12-10 Crucell Holland Bv Vacuna acelular contra pertussis
JP6440687B2 (ja) 2013-04-30 2018-12-19 ドナルド ダンフォース プラント サイエンス センター 抗真菌性植物タンパク質、ペプチド、及び使用方法
CN103255163B (zh) * 2013-05-15 2016-01-27 北京民海生物科技有限公司 一种ev71病毒样颗粒及其制备方法与应用
JPWO2015064517A1 (ja) * 2013-10-28 2017-03-09 国立大学法人岐阜大学 ギ酸脱水素酵素とその利用
US10550164B2 (en) 2015-08-03 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use
EP3922726A1 (de) 2020-06-10 2021-12-15 Erber Aktiengesellschaft Verkürzter promotor für rekombinante genexpression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876197A (en) * 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
GB8600245D0 (en) * 1986-01-07 1986-02-12 Shell Int Research Preparation of 2-arylpropionic acids

Also Published As

Publication number Publication date
AU2443488A (en) 1990-05-03
JPH02124093A (ja) 1990-05-11
DE3789866D1 (de) 1994-06-23
US5389525A (en) 1995-02-14
JP3072993B2 (ja) 2000-08-07
DE3789866T2 (de) 1994-09-22
EP0299108B1 (de) 1994-05-18
EP0299108A1 (de) 1989-01-18
ES2056799T3 (es) 1994-10-16

Similar Documents

Publication Publication Date Title
ATE105858T1 (de) Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung.
DE69133342D1 (de) Rekombinante DNS-Sequenzen kodierend für Enzyme frei von Feedback-Inhibition, Plasmide, die diese Sequenzen enthalten, transformierte Mikroorganismen, nützlich für Produktion aromatischer Aminosäuren, und deren Verfahren zur Herstellung durch Fermentation
DE69119454D1 (de) DNA-Fragment, das ein Polypeptid mit Nitrilhydrataseaktivität kodiert, DNA-Fragment enthaltende Transformante und Verfahren zur Herstellung von Amiden unter Verwendung der Transformante
KR840008695A (ko) 효모표현 시스템에 α-인자 서열을 이용하는 방법
EP0483115A3 (de) Regulatorisches Gebiet zur heterologen Genexprimierung in der Hefe
IL71634A (en) Method for production of processed and secreted biologically active human insulin-like growth factor i and dna constructs used in the above method
KR880014110A (ko) 인체 프로아포지방단백질 a-i의 발현
ATE169956T1 (de) Dna, die für proteine kodiert, die menschliches il-1 binden
DE3854950D1 (de) Vascular-antikoagulierende Proteine, DNA die diese kodieren, Verfahren zu deren Herstellung sowie deren Verwendung
ATE152124T1 (de) Wachstumsfaktor aus parenchymalen lebenszellen, dafür kodierendes gen, verfahren zur herstellung dieses faktors und transformanten
MX9203645A (es) Nuevos interferones de humano y proceso biotecnologico para su produccion.
ES2076926T3 (es) Produccion por tecnologia genetica de factor xiiia.
ATE70302T1 (de) Verfahren zur expression von alpha-1-antitrypsin in bakterien und dessen verwendung in therapeutischen zusammensetzungen sowie vektoren und bakterien fuer ein solches verfahren und deren herstellung.
AU7949991A (en) Cloned n-methylhydantoinase
DE69027466T2 (de) Achromobacter-Protease-I-Gen sowie Genprodukt
GB2067574B (en) Microbiologically prepared polypeptide with the amino acid sequence of proinsulin of a primate dna and plasmids which code for this sequence microorganisms which contain this genetic information and processes for their preparation
EP0267692A3 (en) Production of recombinant human psti, psti polypeptides and their use and corresponding dna
DE68916087T2 (de) System der induzierbaren positiven Regulation zur Verwendung für die Herstellung von heterologen Proteinen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time